Celularity, Inc. (NASDAQ:CELU) Sees Significant Decline in Short Interest

Celularity, Inc. (NASDAQ:CELU) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 381,786 shares, a drop of 24.8% from the November 30th total of 507,957 shares. Based on an average daily volume of 61,204 shares, the short-interest ratio is presently 6.2 days. Currently, 1.6% of the company’s stock are sold short. Currently, 1.6% of the company’s stock are sold short. Based on an average daily volume of 61,204 shares, the short-interest ratio is presently 6.2 days.

Celularity Stock Down 5.3%

Celularity stock traded down $0.06 during trading hours on Wednesday, hitting $1.07. 97,468 shares of the company traded hands, compared to its average volume of 153,273. Celularity has a 1-year low of $1.00 and a 1-year high of $4.35. The firm has a market cap of $30.33 million, a P/E ratio of -0.32 and a beta of 0.77. The firm’s 50-day simple moving average is $1.71 and its two-hundred day simple moving average is $2.27.

Celularity (NASDAQ:CELU) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.62. Celularity had a negative return on equity of 459.57% and a negative net margin of 198.75%.The company had revenue of $5.28 million for the quarter.

Institutional Trading of Celularity

Several institutional investors and hedge funds have recently added to or reduced their stakes in CELU. Yorkville Advisors Global LP acquired a new position in Celularity in the third quarter worth approximately $207,000. Perennial Investment Advisors LLC acquired a new position in shares of Celularity in the 3rd quarter worth $28,000. Vanguard Group Inc. raised its position in shares of Celularity by 35.3% during the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock worth $1,401,000 after purchasing an additional 176,518 shares during the period. HB Wealth Management LLC purchased a new stake in shares of Celularity during the third quarter valued at $84,000. Finally, Bank of America Corp DE increased its stake in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after purchasing an additional 35,023 shares in the last quarter. 19.02% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celularity in a research note on Wednesday, October 8th. WBB Securities raised shares of Celularity from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Tuesday, September 9th. Finally, Wall Street Zen cut shares of Celularity from a “hold” rating to a “sell” rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Celularity presently has an average rating of “Hold” and an average target price of $6.00.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.